<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: Expression of the <z:chebi fb="75" ids="15414">SAM</z:chebi> pointed domain containing ETS transcription factor (SPDEF or prostate-derived ETS factor) is regulated by Atoh1 and is required for the differentiation of goblet and Paneth cells </plain></SENT>
<SENT sid="1" pm="."><plain>SPDEF has been reported to suppress the development of breast, prostate, and <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed levels of SPDEF in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> samples from patients and its <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-suppressive functions in mouse models of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We analyzed levels of SPDEF <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> and protein in more than 500 human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> samples and more than 80 nontumor controls </plain></SENT>
<SENT sid="4" pm="."><plain>Spdef(-/-)and <z:mp ids='MP_0002169'>wild-type</z:mp> mice (controls) were either bred with Apc(Min/+) mice, or given azoxymethane (AOM) and <z:chebi fb="0" ids="52071">dextran</z:chebi> <z:chebi fb="0" ids="32149">sodium sulfate</z:chebi> (DSS), or 1,2-dimethylhydrazine and DSS, to induce <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Expression of Spdef also was induced transiently by administration of <z:chebi fb="9" ids="27902">tetracycline</z:chebi> to Spdef(dox-intestine) mice with established <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, induced by the combination of AOM and DSS or by breeding with Apc(Min/+) mice </plain></SENT>
<SENT sid="6" pm="."><plain>Colon tissues were collected and analyzed for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> number, size, grade, and for cell proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>We also analyzed the effects of SPDEF expression in HCT116 and SW480 human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: In <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> from patients, loss of SPDEF was observed in approximately 85% of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and correlated with progression from <z:mpath ids='MPATH_458'>normal</z:mpath> tissue, to <z:mpath ids='MPATH_270'>adenoma</z:mpath>, to <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Spdef(-/-); Apc(Min/+) mice developed approximately 3-fold more <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumors</z:e> than Spdef(+/+); Apc(Min/+) mice </plain></SENT>
<SENT sid="10" pm="."><plain>Likewise, Spdef(-/-) mice developed approximately 3-fold more <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumors</z:e> than Spdef(+/+) mice after administration of AOM and DSS </plain></SENT>
<SENT sid="11" pm="."><plain>After administration of 1,2-dimethylhydrazine and DSS, invasive <z:mp ids='MP_0002038'>carcinomas</z:mp> were observed exclusively in Spdef(-/-) mice </plain></SENT>
<SENT sid="12" pm="."><plain>Conversely, expression of SPDEF was sufficient to promote cell-cycle exit in cells of established <z:mpath ids='MPATH_270'>adenomas</z:mpath> from Spdef(dox-intestine); Apc(Min/+) mice and in Spdef(dox-intestine) mice after administration of AOM + DSS </plain></SENT>
<SENT sid="13" pm="."><plain>SPDEF inhibited the expression of β-catenin-target genes in mouse <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumors</z:e>, and interacted with β-catenin to block its transcriptional activity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines, resulting in lower levels of cyclin D1 and c-MYC </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: SPDEF is a <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> suppressor and a candidate therapeutic target for colon <z:mpath ids='MPATH_270'>adenomas</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>